Cabaletta Bio (CABA) Stock Price, News & Analysis

Company Overview

Cabaletta Bio, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases. The company's lead product candidate is CABA-201, a fully human anti-CD19 binder for the treatment of Phase 1/2 clinical trials in dermatomyositis, anti-synthetase syndrome, immune-mediated necrotizing myopathy, lupus nephritis, non-renal systemic lupus erythematosus, systemic sclerosis, and generalized myasthenia gravis. It also develops DSG3-CAART, which is in Phase I/II clinical trial for the treatment of mucosal pemphigus vulgaris; and MuSK-CAART, an investigational cell therapy that is in Phase I/II clinical trial for treating patients with anti- muscle-specific kinase antibody positive myasthenia gravis. It has a collaboration with the University of Pennsylvania and the Children's Hospital of Philadelphia; Nanjing IASO Biotherapeutics Co., Ltd; Oxford Biomedica; and WuXi Advanced Therapies, Inc. The company was formerly known as Tycho Therapeutics, Inc. and changed its name to Cabaletta Bio, Inc. in August 2018. Cabaletta Bio, Inc. was incorporated in 2017 and is headquartered in Philadelphia, Pennsylvania.

Key Stats

• Today's Range: $2.25 to $2.45
• 50-Day Range: $2.08 to $4.13
• 52-Week Range: $1.76 to $26.35
• Volume: 867,381 shs
• Average Volume: 1.33 million shs
• Market Capitalization: $113.40 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $24.38
• Consensus Rating: Buy

Cabaletta Bio Stock Analysis - MarketRank™

Cabaletta Bio scored higher than 44% of companies evaluated by MarketBeat, and ranked 672nd out of 955 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.5 / 5
• Analyst Rating: Buy

Consensus Rating

Cabaletta Bio has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 7 buy ratings, 1 hold rating, and no sell ratings.

Amount of Analyst Coverage

Cabaletta Bio has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Cabaletta Bio are expected to decrease in the coming year, from ($2.34) to ($2.82) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Cabaletta Bio is -1.08, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Cabaletta Bio is -1.08, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Cabaletta Bio has a P/B Ratio of 0.42. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

13.20% of the outstanding shares of Cabaletta Bio have been sold short.

Short Interest Ratio / Days to Cover

Cabaletta Bio has a short interest ratio ("days to cover") of 2.6, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Cabaletta Bio has recently increased by 7.14%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Cabaletta Bio does not currently pay a dividend.

Dividend Growth

Cabaletta Bio does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

13.20% of the outstanding shares of Cabaletta Bio have been sold short.

Short Interest Ratio / Days to Cover

Cabaletta Bio has a short interest ratio ("days to cover") of 2.6, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Cabaletta Bio has recently increased by 7.14%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 0.0 / 5
• News Sentiment: 0.00

News Coverage This Week

MarketBeat has tracked 3 news articles for Cabaletta Bio this week, compared to 3 articles on an average week.

Search Interest

Only 22 people have searched for CABA on MarketBeat in the last 30 days. This is a decrease of -33% compared to the previous 30 days.

MarketBeat Follows

Only 13 people have added Cabaletta Bio to their MarketBeat watchlist in the last 30 days. This is a decrease of -24% compared to the previous 30 days.

Company Ownership

• Score: 0.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Cabaletta Bio insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 9.88% of the stock of Cabaletta Bio is held by insiders.

CABA Stock Analysis - Frequently Asked Questions

How have CABA shares performed this year?

Cabaletta Bio's stock was trading at $2.27 at the beginning of the year. Since then, CABA shares have increased by 2.2% and is now trading at $2.32.
View the best growth stocks for 2025 here.

How were Cabaletta Bio's earnings last quarter?

Cabaletta Bio, Inc. (NASDAQ:CABA) released its quarterly earnings data on Thursday, August, 8th. The company reported ($0.56) earnings per share for the quarter, missing analysts' consensus estimates of ($0.55) by $0.01.

When did Cabaletta Bio IPO?

Cabaletta Bio (CABA) raised $87 million in an initial public offering on Friday, October 25th 2019. The company issued 5,800,000 shares at $14.00-$16.00 per share. Morgan Stanley, Cowen and Company and Evercore Group served as the underwriters for the IPO.

Who are Cabaletta Bio's major shareholders?

Cabaletta Bio's top institutional shareholders include Jennison Associates LLC (5.14%), HealthInvest Partners AB (0.51%), Bank of New York Mellon Corp (0.29%) and SG Americas Securities LLC (0.09%). Insiders that own company stock include Steven Nichtberger, Anup Marda, Gwendolyn Binder and Catherine Bollard.
View institutional ownership trends.

How do I buy shares of Cabaletta Bio?

Shares of CABA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Cabaletta Bio own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Cabaletta Bio investors own include NVIDIA (NVDA), Broadcom (AVGO), Arista Networks (ANET), Meta Platforms (META), e.l.f. Beauty (ELF), Jabil (JBL) and Disc Medicine (IRON).

Company Calendar

• Last Earnings: 8/08/2024
• Today: 2/04/2025
• Next Earnings (Estimated): 3/20/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Biological products, except diagnostic
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:CABA
• CUSIP: N/A
• CIK: 1759138
• Web: www.cabalettabio.com
• Phone: 267-759-3100
• Fax: N/A
• Employees: 50
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $24.38
• High Stock Price Target: $50.00
• Low Stock Price Target: $6.00
• Potential Upside/Downside: +962.1%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 9 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($2.15)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-67,680,000.00
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -50.10%
• Return on Assets: -45.49%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 8.11
• Quick Ratio: 8.11

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $5.51 per share
• Price / Book: 0.42

Miscellaneous

• Outstanding Shares: 48,880,000
• Free Float: 44,048,000
• Market Cap: $112.18 million
• Optionable: Optionable
• Beta: 2.47